

## PROGRAM WITH LAST MINUTE CHANGES.

THURSDAY 18 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
8.00	Opening ceremony-dekan of University 08.15-08.30		
8.30	<b>KIDNEY TRANSPLANTATION I</b> Chairmen: Georg Boehming and Mads Homum <b>Søren Schwartz Sørensen</b> (Denmark): ABO-incompatible kidney transplantation Copenhagen experience 08.30-09.00	<b>CARDIOVASCULAR DISEASES I</b> Chairmen: Ulrich Julius and Wolfgang Ramlow <b>Peter Lansberg</b> (Netherlands): LDL-C and HDL-C = black and white for the cardiovascular risk - a critical overview 08.30-09.00	<b>PEDIATRIC APHERESIS I</b> Chairmen: Joseph Schwartz and Motoshi Hattori <b>Alina Casian</b> (UK): Pediatric Apheresis in nephrology 08.30-08.55
9.00	<b>Georg Boehming</b> (Austria): The role of immunoadsorption before and after kidney TX - 20 yrs Vienna experience 09.00-09.30	<b>Pia Kamstrup</b> (Denmark): Lp(a) as cardiovascular risk factor - conclusions from the Copenhagen Cohort study 09.00-09.30	<b>Motoshi Hattori</b> (Japan): Apheresis in the pediatric nephrology Japanese experience 08.55-09.20
9.30	<b>Paolo Malvezzi</b> (France): Effect of double-filtration plasmapheresis for antibody-mediated rejection regarding coagulation parameters and thrombin generation 09.30-09.45	<b>P. Barton Duell</b> (USA): The link between Lp(a) and PCSK9 under apheresis conditions 09.30-10.00	<b>Rachel Pawson</b> (UK): mobilization protocols & success of engraftment in pediatrics 09.20-09.45 <b>Khaled El-Ghariani</b> (UK): Stem cell collections in pediatrics 09.45-10.05
10.00	Coffee		
10.30	<b>IMMUNE APHERESIS I</b> Chairmen: Hiroaki Ogata and Volker Schettler <b>Hiroaki Ogata</b> (Japan): New application for therapeutic apheresis in nephrology 10.30-11.00	<b>CARDIOVASCULAR DISEASES II</b> Chairmen: Mariko Harada-Shiba and Kurt Derfler <b>Anja Vogt</b> (Germany): The Odyssey ESCAPE trial and it's consequences for the application of LDL-apheresis 10.30-11.00	<b>APHERESIS SYMPOSIUM ON: ASFA MEETS ISFA</b> Chairmen: Bruce Sachais and Yoshi Endo <b>Bob Weinstein</b> (USA): Evidence and decision making in Apheresis Medicine 10.30-10.50
11.00	<b>Joanne Kitley</b> (UK): Use of plasma exchange in MG and comparison with NMO – evidence review and proposed mechanism of actions of TPE in those diseases. 11.00-11.30	<b>Mariko Harada-Shiba</b> (Japan): Long-term outcome of apheresis treatment in patients with severe cardiovascular disease resulting from hypercholesterolemia 11.00-11.30	<b>Bruce Sachais</b> (USA) President of ASFA :TPE research ASFA perspective 10.50-11.10

THURSDAY 18 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
11.30	<b>Peter Klein-Weigel</b> (Germany): Immunoadsorption in thrombangitis obliterans 11.30-12.00	<b>Patrick Moriarty</b> (USA): Novel Drug Therapies for the Treatment of Hypercholesterolemia 11.30-12.00	<b>Qualification In Apheresis (QIA) – A New Credential for Apheresis Practitioners</b> <b>Christina Anderson</b> , BSN, RN, HP (ASCP)QIA – What is it and who is it for? 11.10-11.30 <b>Christine Fernandez</b> RN MSN/Ed OCNQIA – How do I prepare for the exam? 11.30-11.50
12.00	ISFA Board Meeting		<b>LUNCH SYMPOSIUM TERUMO BCT Clinical considerations of plasma exchange</b> Centrifugal Therapeutic Plasma Exchange (TPE) vs. membrane TPE – Jan Kielstein Anticoagulant management in therapeutic Plasma Exchange Miguel Lozano Vascular Access: multiple options and single needle – Paolo Malvezzi
13.00	<b>IMMUNE APHERESIS II - AUTOIMMUNE VASCULITIDIES</b> Chairmen: Wladimir Szpirt and Alina Casian <b>Wladimir Szpirt</b> (Denmark) TPE in Vasculitis and Low dose Cyclophosphamide 13.00-13.20	<b>CARDIOVASCULAR DISEASES III</b> Chairmen Patrick Moriarty and Mariko Hirada-Shiba <b>Sotirios Tsimikas</b> (USA): Modern anti-sense technology to lower high Lp(a) - current status and next steps 13.00-13.30	<b>SYMPOSIUM ON: Registries B. Stegmayr (Sweden)</b> Chairmen: Bernd Stegmayr and Robert Weinstein <b>Christian Peter</b> (Germany): From Cardiometabolic to dyslipidemia register 13.00-13.20.
13.30	<b>Alina Casian</b> (UK) - Lung haemorrhage and TPE 13.20-13.40 <b>Mårten Segelmark</b> (Sverige) - Clear Trial - Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 13.40-14.00	<b>Ulrich Julius</b> (Germany): Perspectives of lipoprotein apheresis in patients with high lipoprotein(a) 13.30-14.00	<b>Bernd Stegmayr</b> (Sweden): Update on the WAA apheresis registry 13.20-13.40 <b>Volker Schettler</b> (Germany): The German Lipoprotein Apheresis Register - Current status and future developments 13.40-14.00

THURSDAY 18 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
14.00	<b>Shouchi Fujimoto</b> (Japan): Utility of therapeutic apheresis in ANCA vasculitis - Japanese experience 14.00-14.20	<b>Wolfgang Ramlow</b> (Germany): Still a future for lipoprotein apheresis despite powerful novel drug developments? 14.00-14.30	<b>SYMPOSIUM ON: Apheresis Regulations and Reimbursement Sandra Flora Siami</b> (USA) Therapeutic Apheresis Regulation and Reimbursement in the United States 14.00-14.30
14.30	<b>Zdenka Hrustova</b> (Czech rep.) 1. Plasma exchange in ANCA-associated vasculitis - single-centre experience. 14.20-15.00	<b>Bernd Hohenstein</b> (Germany): the MultiSELCT Lp(a) trial protocol and current status 14.30-15.00	<b>Uwe-H. Wallstab</b> (Germany): Europe - Clinical Evaluation of Medical Devices: 14.30-15.00
	<b>Zdenka Hrustova</b> (Czech rep.) 2. Czech Vasculitis Registry 14.20-15.00		
15.00	Coffee		
15.30	<b>OTHERS - NEW INDICATIONS</b> <i>Chairmen: Bruce Sachais and Heinrich Propphet</i> <b>Carmen Scheibenbogen</b> (Germany): Chronic fatigue syndrome - is there a rationale for apheresis treatment? 15.30-16.00	<b>APHERESIS IN CRITICAL CARE I</b> <i>Chairmen: Steffen Mitzner and Fin Stoltze Larsen</i> <b>Martin Sauer</b> (Germany): Hemodynamics and liver function - important outcome parameters of extracorporeal therapies, especially in septic patients. 15.30-16.00	<b>PHOTOPHERESIS/ HAEMATOLOGY</b> <i>Chairmen: Marietta Nygaard and Lionel Rostaing</i> <b>Rachel Pawson</b> (UK) TPE in Myelomatosis /Waldenström 15.30-15.50
16.00	<b>Petar Kes</b> (Croatia): Treatment of hypertriglyceridemia in a pregnant woman 16.00-16.30	<b>Steffen Mitzner</b> (Germany): Liver support therapies: evidence update 2017 16.00-16.30	<b>Marietta Nygaard</b> (Denmark) Photopheresis in GVH 15.50-16.20
			<b>Manuela Härtel</b> (Germany): Photopheresis in solid organ transplantation 16.20-16.45
16.30	<b>Wolfgang Ries</b> (Germany): CrP adsorption in acute myocardial infarction 16.30-17.00	<b>Fin Stoltze Larsen</b> (Denmark): High Volume TPE in critical hepatic coma 16.30-17.00	<b>P. Kampmann</b> et al. (Denmark): First line apheresis in acquired hemophilia 16.45 -17.00
17.00-17.30	<b>Round table discussion 17.00-17.30</b> Prescription of Volume in TPE with Jan Kielstein and Wladimir Szpirt + moderator Andre Kaplan		

FRIDAY 19 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
8.30	<b>APHERESIS IN CRITICAL CARE - SEPSIS</b> <i>Chairmen: Steffen Mitzner and Shigeto Oda</i> <b>Jan Kielstein</b> (Germany): Apheresis therapy in Sepsis 08.30-09.00	<b>CARDIOVASCULAR DISEASES III</b> <i>Chairmen: Reinhard Klingel and Anja Vogt</i> <b>Mariko Hirada-Shiba</b> (Japan): MTP inhibitor and apheresis therapy in patients with homozygous hypercholesterolemia - experiences from Japan 08.30-08.55	<b>APHERESIS IN COMPLEMENT RELATED CONDITIONS</b> <i>Chairmen: Wladimir Szpirt and Georg Boehmig</i> <b>Andreas Kronbichler</b> (Austria): Biological agents and TPE - can they coexist in the future? 08.30-09.00
9.00	<b>Jens Altrichter</b> (Germany): Personalized cell therapy of sepsis - combining cellular diagnostic and extracorporeal cellular therapy 09.00-09.20	<b>Patrick Moriarty</b> (USA): Retrospective review of the effect of alirocumab on apheresis. 09.00-09.30	<b>Alina Casian</b> - (UK): Update on PEXIVAS 6 years gone 6 months to go. 09.00-09.30
	<b>Yoshihiro Endo</b> (Japan): Apheresis therapy in septic patients - the Japanese perspective 09.20-09.40		
9.30	<b>Steffen Mitzner</b> (Germany): Selective apheresis techniques in critical care 09.40-10.00	<b>Ghodrat Siami</b> (USA): Overview on selective lipid apheresis technologies 09.30-10.00	<b>Andreas Kronbichler</b> (Austria)- TPE strategy in Complement mediated diseases - an overview 09.30-10.00
10.00	Coffee		
10.30	<b>IMMUNE APHERESIS III</b> <i>Chairmen: Hidenori Matsuo and Grit Waitz</i> <b>Anupam Bhattacharjee</b> (UK): Use of plasma exchange in GBS and CIDP - evidence review and proposed mechanism of action of TPE in those diseases 10.30-11.00	<b>CARDIOVASCULAR DISEASES V</b> <i>Chairmen: Wolfgang Ramlow and Patrick Moriarty</i> <b>Tina Z. Khan</b> (UK): Apheresis in unstable angina patients with high Lp(a) - conclusions from a crossover trial 10.30-11.50	<b>SYMPOSIUM ON: APHERESIS IN IMMUNE RELATED CONDITIONS -SLE</b> <i>Chairmen: Alina Casian and Kurt Derfler</i> <b>Andreas Kronbichler</b> (Austria) - Extracorporeal treatment strategies in the management of SLE 10.30-11.00
11.00	<b>Dobri Kiproff</b> (USA): Auto-immunity and Immunosenescence - is there a role for TPE? 11.00-11.30	<b>Claudia Stefanutti</b> (Italy): Pleiotropic effects of lipoprotein apheresis 11.50-11.15	<b>Kurt Derfler</b> (Austria) - Long term TPE results in nephrological disorders - Vienna experience 11.00-11.30

FRIDAY 19 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
11.30	<b>Bernd Hohenstein</b> (Germany): Presentation of coming activities of e-ISFA and Vienna Congress 2018. 11.30-11.50	<b>Reinhard Klingel</b> (Germany): Clinical and molecular characterisation of patients treated by long-term lipoprotein apheresis due to Lp(a)-hypolipoproteinemia according to German national guidelines. 11.15-11.35  <b>Ulrich Julius</b> (Germany): Perspectives of lipoprotein apheresis in patients with high lipoprotein(a) 11.35-12.00	<b>Kusaoi M</b> (Japan): Separation of circulating micro RNAs using apheresis in patient with systemic lupus erythematosus 11.30-12.00
12.00			<b>LUNCH SYMPOSIUM FRESENIUS</b> Immunoabsorption in Membranous Nephropathy: Insights & Updates from the Manchester Working Group. <b>Dr. Patrick Hamilton</b> , Manchester, UK Immunoabsorption in Early Dementia – Rationale and First Results in Vascular and Cognitive Outcome. <b>PD Dr. Sönke Langner</b> , Greifswald, Germany Immunoabsorption in Multiple Sclerosis – Current Evidence Level and Outlook. <b>Dr. Johannes Dorst</b> , Ulm, Germany
13.00	<b>MISCELLANEOUS I /NEW INDICATIONS:</b> <i>Chairmen: Bernd Hohenstein and Ken Yamaji</i> <b>Bob Weinstein</b> (USA): Emerging indications for Therapeutic plasma-apheresis based on recent case reports. 13.00-13.30	<b>HUS-TTP/ PRECLAMPSIA</b> <i>Chairmen: Jan Kielstein and Marie Scully</i> <b>Henning Hagmann</b> (Germany): The role of apheresis therapy in preeclampsia - rationale and first clinical results 13.00-13.25	<b>ORAL COMMUNICATIONS</b> <i>Chairmen: Stefan Mitzner and Wolfgang Ramlow</i> <b>Frederick Sanderson</b> (France): Evaluation of a new automated red cell exchange procedure in routine use 13.00-13.20

FRIDAY 19 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
13.30	<b>Isaac Eliaz</b> (USA) -The role of Galectin-3 removal in inflammatory and fibrotic diseases. 13.30-14.00	<b>Marie Scully</b> (UK) TTP and atypical HUS in Pregnancy 13.25-13.50	<b>Jens Altrichter</b> (Germany): Terminal sterilization of extracorporeal devices 13.20-13.40
14.00	<b>Grit Waitz</b> (Germany): Adsorptive cytapheresis in ulcerative colitis - Current practice in Europe 14.00-14.30	<b>Diana Karpman</b> (Sverige) Microvesicles in hemolytic uremic syndrome 13.50-14.15  <b>Marie Scully</b> (UK): Apheresis and acquired TTP -Titan study with Caplacizumab 14.15-14.35	<b>Yuki Hattori</b> (Japan): Recurrent Sweet syndrome successfully treated with granulocyte and monocyte apheresis. 13.40-14.00  <b>Noriyuki Hattori</b> (Japan): Polymethylmethacrylate membrane hemofilter remove at least 10 kinds of cytokines in septic pts. with cytokine storm 14.00-14.20
14.30	<b>Lionel Rostaing</b> (France) HLA incompatible kidney transplantation: different strategies particularly regarding apheresis. 14.30-15.00	<b>Claudia Stefanutti</b> (Italy): TPE in Pregnancy: Differential Indications with positive maternal and fetal outcome. 14.35-15.00	<b>Jon Waerst Gregersen</b> (Denmark): Early plasma exchange improves outcome in PR3-ANCA vasculitis - A three year follow-up study 14.20-14.40  <b>Tomoharu Shimizu</b> (Japan): The prognosis and indication of blood purification in a patient with colorectal perforation according to new definition of Sepsis-3 14.40-15.00
15.00	Coffee		
15.30	<b>MISCELLANEOUS III</b> <i>Chairmen: Robert Weinstein and Shigau Ikeda</i> <b>Yutaka Eguchi</b> (Japan): Apheresis in critical care using plasma diafiltration 15.30-16.00	<b>MISCELLANEOUS IV</b> <i>Chairmen: Wolfgang Ram-low and Dusit Lumlertgul</i> <b>Heinrich Prophet</b> (Germany): Long-term surveillance of atherosclerosis by carotid ultrasound in a single apheresis center cohort 15.30-16.00	<b>ORAL COMMUNICATIONS</b> <i>Chairmen: Joseph Schwartz and Volker Witt</i> <b>Volker Witt</b> (Austria): Indications and technical challenges for Apheresis in children 15.30-16.00  <b>Anna Maria Pugliese</b> (Argentina): Overview of therapeutic plasma exchange in pediatrics. Experience in a third level hospital between 1994-2016 16.00-16.20

FRIDAY 19 MAY 2017			
	CARSTENSEN	LUMBYE	PJERROT
16.00	<b>Robert Weinstein</b> (USA): Apheresis in tandem with hemodialysis: is supplemental calcium always necessary? 16.00-16.30	<b>Ken Yamaji</b> (Japan): Apheresis treatment in collagen disease - the Japanese perspective 16.00-16.30	<b>Wolfgang Ries</b> (Germany): "CrP adsorption in pancreatitis" 16.20-16.40
16.30	Round table discussion 16.30-17.00 Tandem Apheresis PRO Lionel Rostaing and AGAINST Wladimir Szpirt + moderator Bob Weinstein	<b>Dusit Lumlertgul</b> (Thailand): Hemorheopheresis for diabetic foot syndrome no response 16.30-17.00	<b>Elie Moubarak</b> (Lebanon): Familial hypercholesterolemia: efficiency and safety of the treatment - Lebanese experience 16.40-17.00
17.00	<b>A-HUS SYMPOSIUM SUPPORTED BY UNRESTRICTED GRANT FROM ALEXION - Moderator B. Hohenstein</b> <b>Seppo Meri</b> pathogenesis of aHUS <b>Fadi Fakhouri</b> - a-HUS Treatment challenges <b>T. Sakari Jokiranta</b> -a-HUS and complement		
18.00	<b>ISFA General Assembly</b>		
19.00	Congress banquet - boat canal trip 30 minutes and dinner at 20.00 Langelinie Pavillonon		

SATURDAY 20 MAY 2017		
	CARSTENSEN	LUMBYE
9.00	<b>MISCELLANEOUS V</b> <i>Chairmen: Heinrich Prophet and Steffen Mitzner y)</i> <b>Toshihide Naganuma</b> (Japan): Selective apheresis in ABO-incompatible kidney transplantation 09.00-09.20 <b>Steffen Mitzner</b> (Germany): Cytokine adsorption in critically ill patients 09.20-09.40	<b>TECHNICAL ISSUES</b> <i>Chairmen: Michio Mineshima and Paul Malchesky</i> <b>Paul Malchesky</b> (USA): Membrane Plasma Separation and Therapeutic Plasma Filtration 09.00-09.20 <b>Michio Mineshima</b> (Japan): Membrane technology for apheresis 09.20-09.40
9.30	<b>Jakob Gubensek</b> (Slovenia): A decade of experience with the treatment of antibody-mediated rejection after kidney transplantation 09.40-10.00	<b>Marie Scully</b> (UK): A single-center prospective study on the safety of TPE using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. 09.40-10.00
10.00	Coffee	
11.00	<b>REGULATORY ISSUES + GUIDELINES</b> <i>Chairmen: Bob Weinstein and Joseph Schwartz</i> <b>Shepard Bentley</b> (USA): Current regulatory aspects for apheresis systems from FDA 11.00-11.20	<b>APHERESIS HISTORY</b> <i>Chairmen: Wolfgang Ramlow and Andre Kaplan</i> <b>Horst Klinkmann</b> (Germany): The changing Pattern (since 1978) of Therapeutic Apheresis - a historical reflection. 11.00-11.20
11.30	<b>Josef Schwartz</b> (USA): Development and implementation of guidelines - what to be learned from ASFA? 11.20-11.40 <b>Uwe-H. Wallstab</b> (Germany): New European Medical Device Regulation - Significant changes in the device approval process 11.40-12.00	<b>Paul Malchesky</b> (USA): The Early Cleveland Clinic Experiences in Therapeutic Apheresis 11.20-11.40 <b>Andre Kaplan</b> (USA) TPE in the 70ties and 80ties - USA experience. 11.40-12.00
12.00	Lunch	
13.00	<b>ISFA CLOSING SESSION</b> <i>Chairmen: Wladimir Szpirt and Yoshiro Endo</i> <b>Bernd Hohenstein</b> (Germany): Future perspectives of immune apheresis 13.00-13.30  Closing ceremony See You in Kyoto 2019.	